IPI-145-18: A Phase 1b Study of IPI-145 Administered in Combination with Obinutuzumab in Patients with CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor (BTKi) - Regional Cancer Care Associates LLC

Clinical Trials

IPI-145-18: A Phase 1b Study of IPI-145 Administered in Combination with Obinutuzumab in Patients with CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor (BTKi)

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Infinity
Protocol Number
IPI-145-18
Cancer Diagnosis
To Learn More Call
201-510-0910